# EDGAR Filing Document

**Accession Number:** 0001798749
**File Stem:** 0001193125-26-096706
**Filing Date:** 2026-3
**Character Count:** 8288
**Document Hash:** d51ccae8dea5a7719bd0e184da1e025d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-096706.hdr.sgml**: 20260306

**ACCESSION NUMBER**: 0001193125-26-096706

**CONFORMED SUBMISSION TYPE**: POS EX

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260306

**DATE AS OF CHANGE**: 20260306

**EFFECTIVENESS DATE**: 20260306

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Jade Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001798749
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 831377888
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** POS EX
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-292369
- **FILM NUMBER:** 26731613

**BUSINESS ADDRESS:**
- **STREET 1:** 221 CRESCENT ST.
- **STREET 2:** BUILDING 23, SUITE 105
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453
- **BUSINESS PHONE:** (781) 312-3013

**MAIL ADDRESS:**
- **STREET 1:** 221 CRESCENT ST.
- **STREET 2:** BUILDING 23, SUITE 105
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aerovate Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20200103

**As filed with the Securities and Exchange Commission on March 6, 2026** 

**Registration No. 333-292369** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**Post-Effective Amendment No. 1** 

**TO** 

**FORM S-1** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

**JADE BIOSCIENCES, INC.** 

**(Exact name of registrant as specified in its charter)** 

---

| | | |
|:---|:---|:---|
| **Nevada** | **2836** | **83-137788** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(Primary Standard Industrial**<br> **Classification Code Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**221 Crescent St., Building 23** 

**Suite 105** 

**Waltham, MA 02453** 

**(781) 312-3013** 

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive office)** 

**Tom Frolich** 

**Chief Executive Officer** 

**Jade Biosciences, Inc.** 

**221 Crescent St., Building 23** 

**Suite 105** 

**Waltham, MA 02453** 

**(781) 312-3013** 

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

***Copies to:***

**Cheston Larson** 

**Matt Bush** 

**Anthony Gostanian** 

**Latham & Watkins LLP** 

**12670 High Bluff Drive** 

**San Diego, California 92130** 

**(858) 523-5400** 

**Approximate date of commencement of proposed sale to the public:** From time to time after the effective date of this Registration Statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ (333-292369)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large Accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒

**This Post-Effective Amendment No. 1 shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(d) under the Securities Act of 1933, as amended.** 

------

**EXPLANATORY NOTE** 

This Post-Effective Amendment No. 1 (this "Amendment") to the Registration Statement on Form S-1 of Jade Biosciences, Inc. (File No. 333-292369), initially filed on December 22, 2025 and declared effective by the Securities and Exchange Commission on December 30, 2025 (the "Registration Statement"), is being filed as an exhibit-only filing solely to file the consent of PricewaterhouseCoopers LLP with respect to its report dated March 6, 2026 relating to the financial statements of Jade Biosciences, Inc. contained in its Annual Report on Form 10-K for the year ended December 31, 2025 and included in the Prospectus Supplement No. 1 dated March 6, 2026 filed pursuant to Rule 424(b)(3), filed herewith as Exhibit 23.1 (the "Consent"). Accordingly, this Amendment consists only of the facing page, this explanatory note, Item 16 of Part II of the Registration Statement, the signature pages to the Registration Statement and the Consent. The prospectus and the balance of Part II of the Registration Statement are unchanged hereby and have been omitted.

**Part II** 

**INFORMATION NOT REQUIRED IN PROSPECTUS** 

**Item 16. Exhibits and Financial Statement Schedules.** 

**(a) Exhibits.** 

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 23.1\* | [Consent of PricewaterhouseCoopers LLP](d35909dex231.htm) |

---

\* Filed herewith.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, Commonwealth of Massachusetts, on March 6, 2026.

---

| | |
|:---|:---|
| **JADE BIOSCIENCES, INC.** | **JADE BIOSCIENCES, INC.** |
| By: | /s/ Bradford Dahms |
| Name: | Bradford Dahms |
| Title: | Chief Financial Officer and Treasurer |

---

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Tom Frohlich | Chief Executive Officer & Director<br> (Principal Executive Officer) | March 6, 2026 |
| Tom Frohlich | Chief Executive Officer & Director<br> (Principal Executive Officer) | March 6, 2026 |
| /s/ Bradford Dahms | Chief Financial Officer and Treasurer | March 6, 2026 |
| Bradford Dahms | (Principal Financial Officer and Principal Accounting Officer) |  |
| \* | Chair of the Board | March 6, 2026 |
| Eric Dobmeier, J.D. |  |  |
| \* | Director | March 6, 2026 |
| Chris Cain, Ph.D. |  |  |
| \* | Director | March 6, 2026 |
| Tomas Kiselak |  |  |
| \* | Director | March 6, 2026 |
| Lawrence Klein, Ph.D. |  |  |
| \* | Director | March 6, 2026 |
| Erin Lavelle |  |  |

---

---

| | | |
|:---|:---|:---|
| \* | By: | /s/ Bradford Dahms |
|  | Name: | Bradford Dahms |
|  | Title: | Attorney-in-fact |

---

## Exhibit 23.1

**Exhibit 23.1** 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the use in this Registration Statement on Form S-1 of Jade Biosciences, Inc. of our report dated March 6, 2026 relating to the financial statements of Jade Biosciences, Inc., which appears in the Prospectus Supplement of Jade Biosciences, Inc. dated March 6, 2026, which forms a part of this Registration Statement. We also consent to the reference to us under the heading "Experts" in such Registration Statement.

/s/ PricewaterhouseCoopers LLP

Boston, Massachusetts

March 6, 2026